We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00711087
Recruitment Status : Terminated (Funds no longer available)
First Posted : July 8, 2008
Results First Posted : October 9, 2015
Last Update Posted : January 6, 2021
U.S. Department of Education
Information provided by (Responsible Party):
Christopher Patrick Smith, Baylor College of Medicine

Brief Summary:

The purpose of this study is to see what the effect of Botox has on bladder function for those who have recently suffered spinal cord injury. We also will study bladder tissue levels of NGF (nerve growth factor) that can tell us how the nerves to the bladder are healing after injury.

Consenting male and female cervical and high thoracic (T10 and above) SCI patients will be identified within the first 6-7 weeks after SCI and randomized to two external urethral sphincter injection groups. Each group will be injected within 8 weeks after SCI (Day 0) and 3 months later (Day 90). The injection paradigm will consist of: Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90; Group 2-sham saline injections on both Day 0 and Day 90. Injections will be performed under local anesthesia using standard flexible cystoscopic equipment.

Use of placebo is justified because: 1. there have been documentation of nerve desensitization with dry needling (i.e. acupuncture) and wet needling (i.e. saline)--therefore, to truly demonstrate benefit of Botox over just the needle insertion into the sphincter muscle or injection of the diluent saline, a sham saline injection group is included, 2. the injection procedure itself is minimally invasive and not expected to result in any complications.

Subjects who qualify and have signed the informed consent document will be randomized into two groups, those receiving the BTX-A and those receiving placebo. Blinding will be performed by the TIRR pharmacy department who will provide Botox and placebo in identical syringes so that the treating staff will be blinded. Pharmacists will ensure patients receive the same agent at the time of the second injection. Unblinding will occur at the end of the study or if complications necessitate breaking of the code. Both groups will undergo urodynamic testing to document before and after treatment data. Bladder biopsies will be taken prior to treatment in both groups that will be analyzed for nerve growth factor. Three day voiding diaries will be kept and reviewed with the study coordinator at the follow up visits. Quality of life questionnaires will be completed at each follow up visit. The treatments will take place on Day 0 and Day 90. Follow up visits will occur at Day 120, 16 month, and 28 months.

Condition or disease Intervention/treatment Phase
Neurogenic Bladder Dysfunction Nos Spinal Cord Injury Drug: BOTOX-A Other: Saline injection Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Botulinum Toxin A Treatment of Detrusor External Sphincter Dyssynergia During Early Spinal Cord Injury (Protocol #H-20344)
Study Start Date : July 2007
Actual Primary Completion Date : February 2010
Actual Study Completion Date : February 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: ARM 2
Subjects randomized to receive placebo (saline) sham saline injections on Days 0 and 90.
Other: Saline injection
Group 2-sham saline injections on both Day 0 and Day 90.

Active Comparator: ARM 1
Subjects randomized to receive 100 units BOTOX-A injections on Days 0 and 90.
Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
Other Names:
  • BTX-A
  • Botulinum Toxin Type A

Primary Outcome Measures :
  1. A Change in DLPP of 20cm H2O at Day 30 and Day 120 in the BTX-A Injected Group (Group 1) Compared to the Sham Saline Injected Group (Group 2). [ Time Frame: 2.5 years ]
    This outcome measure was not able to be determined due to the subject being lost to follow-up. The subject no longer returns phone calls or visits the clinic.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or Females between ages of 18-50
  • Patient weighs over 111 pounds
  • Patient has documented Spinal Cord Injury T10 or above Thoracic Level by ASIA Score less than 8 weeks prior to the start of the study. Both complete and incomplete spinal cord injuries will be included in this study.
  • Ability to complete all study requirements including voiding diary and to attend all scheduled study visits, in the opinion of the investigator
  • Written informed consent has been obtained
  • Patient has negative pregnancy test result if female and of child-bearing potential
  • Written authorization for use and release of Health and Research Study Information has been obtained
  • Patient or family member is willing and able to perform clean intermittent catheterization for duration of this study

Exclusion Criteria:

  • Patient has received anticholinergic medication for the treatment of overactive bladder before randomization into the study
  • Patient has history or evidence of any pelvic or urological abnormalities, bladder or urethral surgery or disease, other than neurogenic bladder related to spinal cord injury, that may impact bladder function
  • Patient has significant stress urinary incontinence, determined by patient history, in the opinion of the investigator
  • Neurogenic detrusor overactivity (greater than 10cm elevation in pdet pressure) at baseline urodynamic screening (Day 0)
  • Patient found to have significant baseline renal pathology (e.g. hydronephrosis, stones, renal mass) at Day -7
  • Patient has a history of two or more treated urinary tract infections within 6 months of screening Day -7
  • Patient has urinary tract infection defined as a bacteriuria count of greater than 105/ml conjoint with leukocyturia greater than 5hpf at screening Day -7
  • Patient has asymptomatic urinary tract infection, defined as positive nitrites, leukocyte esterase and or blood on urine dipstick reagent strip at randomization Day 0
  • Patient has history of unexplained hematuria or unexplained hematuria if greater than 5 RBC's/hpf are present at screening Day -7
  • Patient has active genital infection, other than genital warts, either concurrently or within 4 weeks prior to screening Day -7
  • Patient has history of interstitial cystitis, in the opinion of the investigator
  • Patient has evidence of urethral obstruction, in the opinion of the investigator at screening Day -7 or randomization Day 0
  • Patient uses medications with anti-platelet or anti-coagulant effects (except Lovenox) within 10 days of randomization Day 0. Lovenox 30mg SQ every 12 hours is standard of care after SCI until 2-3 months post injury. Lovenox will be stopped 24 hours before and for 48 hours after each sphincter injection or bladder biopsy procedure.
  • Patient has hemophilia, or other clotting factor deficiencies or disorders that cause bleeding diathesis
  • Patient has previously been treated with any endovesical pharmacologic agent (e.g. capsaicin, resiniferatoxin)
  • Patient has had previous or current botulinum toxin therapy of any serotype for any condition
  • Patient has a known allergy or sensitivity to any components of the study medication, anesthetics or antibiotics to be used during the study
  • Any medical condition that may put the patient at increased risk with exposure to Botox® including diagnosed myasthenia gravis, Eaton-Lambert syndrome or amyotrophic lateral sclerosis
  • Females who are pregnant, nursing or planning a pregnancy during the study or females of child-bearing potential who are unable or unwilling to use a reliable form of contraception during the study
  • Current or previous participation in another therapeutic study within 30 days of screening Day -7
  • Any condition or situation which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00711087

Layout table for location information
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Memorial Hermann Hospital/The Institute of Rehabilitation and Research
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
U.S. Department of Education
Layout table for investigator information
Principal Investigator: Christopher P. Smith, MD Baylor College of Medicine
Layout table for additonal information
Responsible Party: Christopher Patrick Smith, Associate Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00711087    
Other Study ID Numbers: H-20344
First Posted: July 8, 2008    Key Record Dates
Results First Posted: October 9, 2015
Last Update Posted: January 6, 2021
Last Verified: January 2021
Keywords provided by Christopher Patrick Smith, Baylor College of Medicine:
Spinal Cord Injury
Botulinum toxin (BOTOX-A
Detrusor External Sphincter Dyssynergia
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Urinary Bladder, Neurogenic
Wounds and Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Neurologic Manifestations
Urinary Bladder Diseases
Urologic Diseases
Botulinum Toxins
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents